Biosimilar drugs step up complexity


The first ever generic monoclonal antibody therapies have been recommended for approval in Europe. The two biosimilar versions of infliximab (Johnson & Johnson’s Remicade) have passed assessment by the European Medicines Agency’s committee for medicinal products for human use, but will need to be fully approved by the European commission before they can be marketed.

Monoclonal antibodies are significantly larger and more complex than previously approved biosimilars, which include growth hormones and erythropoietin. Proving that they are functionally similar to the original drug is therefore complex. Both manufacturers, Celltrion and Hospira, had to complete human trials to prove that their generic infliximab products were as safe and effective as Remicade in treating autoimmune diseases.

Johnson & Johnson still has patent protection for Remicade in the majority of European countries. This means that the biosimilars, if finally approved, will either have to launch first in peripheral markets, or try to overturn the patent in court.


Related Content

Cast from the same mould?

31 May 2011 Premium contentFeature

news image

Development of generic biological drugs is gathering momentum. But as Rajendrani Mukhopadhyay finds out, the welcome they are...

US poised to approve its first ‘biosimilar’ drug

9 January 2015 Business

news image

FDA panel recommends Sandoz’s copy of Amgen’s Neupogen

Most Read

Agatha Christie, the queen of crime chemistry

28 August 2015 Feature

news image

Kathryn Harkup looks at how Agatha Christie used her chemical training in her detective novels

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

A risky business

28 August 2015 In the Pipeline

news image

Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe

Exploiting the data mine

13 August 2015 Feature

news image

Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, repor...